Research programme: metabolic disorders therapy - Biovitrum/Pharmacopeia

Drug Profile

Research programme: metabolic disorders therapy - Biovitrum/Pharmacopeia

Latest Information Update: 18 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biovitrum; Pharmacopeia Drug Discovery
  • Developer Biovitrum; Pharmacopeia
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus; Metabolic disorders

Most Recent Events

  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
  • 14 Mar 2007 Preclinical development is ongoing
  • 29 Oct 2004 Preclinical trials in Metabolic disorders in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top